ArticleTranslational oncology2025
YTHDF2 regulates the adriamycin (ADM) resistance in NKTCL by modulating the m6A modification of SLC16A9.
Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reading the tumour at single-cell resolution: Original research in the Precision Therapeutics special issue.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextNatural killer/T-cell lymphoma (NKTCL) is an aggressive malignancy with a high propensity for drug resistance, particularly to anthracyclines like adriamycin (ADM). The molecular mechanisms of ADM resistance in NKTCL are not fully understood.
objectiveIn this study, we aimed to elucidate the role of YTHDF2 in the regulation of SLC16A9 mRNA stability and its implications in ADM resistance in NKTCL. MATERIALS &
methodsThe study examined the expression changes of SLC16A9 under varying concentrations of ADM and manipulated the expression levels of SLC16A9 and YTHDF2 through overexpression and knockdown. By analyzing the levels of m6A modification, it was revealed that YTHDF2 regulates SLC16A9 expression via the m6A pathway, thereby influencing ADM resistance. This conclusion was further validated by in vivo experiments.
resultsOur results showed that overexpression of SLC16A9 enhanced ADM resistance, while knockdown of SLC16A9 increased sensitivity to ADM. Further investigation revealed that ADM treatment reduces m6A modification levels on SLC16A9 mRNA, which is associated with decreased binding of YTHDF2 to SLC16A9 mRNA, leading to increased SLC16A9 expression. We also found that overexpression of YTHDF2 reduced SLC16A9 expression and increased ADM sensitivity, whereas knockdown of YTHDF2 had the opposite effect. In vivo experiments using a nude mouse model further confirmed that SLC16A9 knockdown reduces tumor growth and enhances sensitivity to ADM.
conclusionsour study provides direct evidence that YTHDF2 modulates ADM resistance in NKTCL by regulating the m6A modification of SLC16A9. Targeting the YTHDF2-m6A-SLC16A9 axis may offer a novel therapeutic strategy to overcome chemotherapy resistance in NKTCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.